1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
600EC2E1C4D99FD5C652579090034FAE6
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/oncology-market-entry-market-constituents-access-insights-success-factors?opendocument
18
19opendocument
2034.228.38.35
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Market Entry and Oncology

Payer Factors that Shape a Successful Oncology Market Entry: Education and Access Insights

ID: 5156


Features:

14 Info Graphics

13 Data Graphics

100+ Metrics

6 Narratives


Pages/Slides: 36


Published: Pre-2013


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Payer Factors that Shape a Successful Oncology Market Entry: Education and Access Insights"

STUDY OVERVIEW

While many factors affect a pharmaceutical new product launch, it's recognized that payers have become a critical factor in how an oncology product fares in the marketplace. In response, organizations have incorporated a number of payer-related activities into their pre-launch and launch plans. In particular, launch leaders have learned to focus their efforts on educating payers about a new oncology product and working with private and public payers to gain access for new products at or as soon as possible following launch.

Best Practices, LLC conducted this research study to discover successful strategies and tactics for educating payers on new therapies and winning managed markets access for new oncology products. Launch leaders and managed markets executives can use this research to compare their approach to these payer-related launch interactions with the approaches used by leading organizations. This study contains two segments: an oncology segment and a total benchmark class segment.


KEY TOPICS

  • Payer Education
  • Preparing Market Constituents
  • Access Insights & Success Factors
  • Winning Hospital Formulary Access


SAMPLE METRICS
  • Effectiveness rating of early payer education and engagement activities that prove most critical to market entry and success
  • Importance rating of educating and winning support from payers and other stakeholders in order to enter market, win share, and grow market
  • Gauging whether list of factors important to payers will increase or decrease in importance during the next two years.
  • Importance rating of different strategies and tactics for winning new product acceptance in the hospital market


SAMPLE KEY FINDINGS
  • Engaging Payers With A Focus On Value: Engage payers early and across multiple fronts. Be prepared to speak to their interests on price and reimbursement – and be able to convert price-based conversations into value-based conversations illuminating health outcomes, comparative effectiveness and most valued label attributes.


METHODOLOGY

The research employed a data gathering approach that gleaned quantitative data from seven leaders in oncology, although their participation varied across the question set. The total benchmark class included 44 executives and managers from 38 leading companies in pharmaceutical, biotechnology and medical device industries. In addition, nine executives participated in in-depth interviews.


Industries Profiled:
Pharmaceutical; Medical Device; Biotech; Health Care; Chemical; Manufacturing; Diagnostic; Consumer Products; Media


Companies Profiled:
GlaxoSmithKline; Bristol-Myers Squibb; Roche; Lilly; Novartis; Merck; AstraZeneca; Genentech; Phillips; TGC MedTech; MedImmune; Abbott; Amgen; Bayer; Actelion; Cephalon; Inc.; Teva Neuroscience; Novo Nordisk; Amylin; Laboratorios Deramtologicos Darier; IDS Canada; UCB Pharma; Bayer Schering Pharma; Quintiles; MerckSerono; Servier; Ther-Rx; ProCaps Laboratories; Baxter Healthcare; Urologix; Synapse biomedical; Talecris; NicOx; Eisai; Direct Supply; Shire; ChemGenex Pharmaceuticals; Takeda Pharmaceuticals


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.